The company, launched with help from ex-Novartis executives, is targeting glutamate signaling in the brain to help treat ...

Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...

New research to be presented at this year’s European Congress on Obesity (ECO 2025, Malaga, Spain, 11-14 May) shows that having an overweight or obese trajectory during childhood is associated with an ...

Danish drugmaker Novo Nordisk has bought global rights to China-based United Laboratories International's so-called "triple-G ...

First, Novo Nordisk is expanding its program to sell Wegovy GLP-1 weight loss drugs at discounted prices. Second, Novo is ...

German software developer SAP SE unseated Danish weight-loss drug maker Novo Nordisk A/S as Europe’s most-valuable public ...

Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity ...

The licensing pact adds a second so-called "triple agonist" to the Danish drugmaker's portfolio as competition with Lilly and other contenders heats up.

Novo will license UTB251, a triple hormone receptor agonist that in mid-2023 achieved promising weight reduction in a ...

Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt after a series of trial results have left investors feeling unsatisfied.

The Board of Alders passed and Mayor Justin Elicker signed new restrictions on tobacco and vape retailers, prohibiting almost ...